How to Reduce Host Cell Protein (HCP) to Regulatory Limits

What Are Host Cell Proteins and Why Do They Matter?

Host cell proteins (HCPs) are process-related impurities derived from the expression host organism — typically CHO, HEK293, or E. coli cells — that co-purify with recombinant biologic drug substances. Reducing HCP levels to acceptable limits is a critical quality requirement for every biologic, because residual HCPs can compromise patient safety and product stability.

CHO cell culture harvest typically contains 100,000–300,000 ppm HCP relative to the product (where 1 ppm = 1 ng HCP per mg product). This complex mixture of hundreds to thousands of individual host proteins must be reduced by 4–5 logs to reach the <100 ppm target expected for most monoclonal antibodies.

HCP contamination matters for three reasons:

• Immunogenicity — Foreign proteins can trigger anti-drug antibody (ADA) responses. PLBL2 induced immune responses in patients at levels as low as 0.2–0.4 ppm.
• Product stability — Lipases (LPLA2, LPL) degrade polysorbate 20/80 excipients, generating free fatty acid particles that cause sub-visible particulate formation.
• Enzymatic activity — Proteases like cathepsins can cleave the antibody, increasing fragmentation during hold and storage.

The HCP level in drug substance is generally classified as a critical quality attribute (CQA) per ICH Q6B, requiring validated assays and process controls throughout development and manufacturing.

Regulatory Expectations for HCP Levels

Regulators do not mandate a single universal HCP limit — acceptable levels are evaluated case-by-case based on the product, dose, route, and frequency of administration. However, the industry has converged on practical thresholds backed by decades of clinical experience.

The FDA guidance on process validation states: “Whenever possible, contaminants introduced by the recovery and purification process should be below detectable levels using a highly sensitive analytical method.” In practice, for a sensitive HCP ELISA with a limit of quantitation (LOQ) of 1–5 ng/mL, this translates to single-digit ppm in the final drug substance.

ICH Q6B requires a “sensitive assay capable of detecting a wide range of protein impurities” and expects manufacturers to demonstrate adequate HCP clearance across the downstream process. The specification is set during clinical development and locked at BLA filing, supported by process characterization data showing consistent clearance.

HCP Clearance Across the Purification Train

A well-designed mAb purification process achieves 4–5 log HCP clearance across 3–4 chromatography steps plus filtration. Each step contributes a defined log reduction value (LRV), and the cumulative clearance must consistently deliver drug substance below the specification limit.

The capture step (Protein A) does the heavy lifting, removing >99% of HCPs in a single operation. However, the residual 500–5,000 ppm after capture contains the most problematic species — those that associate directly with the antibody product and resist removal by affinity selectivity alone.

HCP Reduction Waterfall: From Harvest to Drug Substance

Optimizing Protein A Wash Stringency for HCP Removal

The Protein A wash step is the single most impactful lever for HCP clearance in mAb purification. An optimized post-load wash can reduce HCP in the eluate by 2–10× compared to a standard equilibration buffer wash, without affecting product recovery.

HCPs persist after Protein A capture through two mechanisms:

1. Resin interaction — HCPs bind directly to the Protein A ligand or agarose backbone via non-specific electrostatic or hydrophobic interactions.
2. Product association — HCPs bind to the mAb itself and co-elute when the antibody is released at low pH. These “hitchhiker” HCPs are the harder population to clear.

Shukla and Hinckley (2008) demonstrated that product-associated HCPs dominate the residual population after Protein A, meaning wash optimization must focus on disrupting protein–protein interactions rather than protein–resin interactions.

Salt Wash: The 250 mM NaCl Threshold

Increasing NaCl concentration in the wash buffer disrupts electrostatic HCP–mAb interactions. Research shows that 250 mM NaCl achieves the bulk of salt-mediated HCP reduction, with diminishing returns above this concentration.

Advanced Wash Additives

For products with persistent HCP co-purification, additives beyond NaCl can further disrupt product–HCP interactions:

Polishing Chromatography for Final HCP Clearance

Polishing steps reduce HCP from the low-thousands (post-capture) to single-digit ppm in the drug substance. The choice of polishing mode — and whether to use bind-and-elute or flow-through — determines HCP clearance efficiency.

Anion Exchange (AEX) in Flow-Through Mode

AEX in flow-through is the most common first polishing step for mAb HCP clearance. At neutral pH, most mAbs (pI 7–9) carry a net positive charge and flow through the column, while negatively charged HCPs, DNA, and endotoxin bind to the resin.

Typical operating conditions: pH 7.2–7.8, conductivity 1.6–5.6 mS/cm. Under these conditions, AEX flow-through achieves 2–3 LRV for HCP at feed concentrations around 1,000 ppm, yielding product with 7–26 ppm HCP. At feed concentrations below 100 ppm, clearance drops to <1 LRV because the remaining HCPs are predominantly product-associated species that co-migrate with the antibody.

Cation Exchange (CEX) in Bind-and-Elute Mode

CEX captures the mAb at low salt and elutes with a salt gradient, separating product from HCP variants with different charge profiles. CEX as a first polish after Protein A typically reduces HCP to 15–90 ppm depending on loading (10–30 mg/mL) and elution conductivity (3–7 mS/cm).

Mixed-Mode Chromatography

Mixed-mode resins (e.g., Capto Adhere, CHT ceramic hydroxyapatite) combine ionic and hydrophobic selectivity, providing orthogonal HCP clearance. These are particularly effective against product-associated HCPs that escape both AEX and CEX, reducing HCP to <20 ppm in flow-through mode at 6 mS/cm conductivity.

High-Risk HCPs: The Hitchhiker Problem

Not all HCPs pose equal risk. A 2021 multi-company collaborative study by the BioPhorum Development Group (Jones et al.) catalogued specific “high-risk” HCPs that recurrently co-purify with CHO-derived mAbs and pose outsized safety or quality risks.

These HCPs persist not because the purification process fails generally, but because they bind directly to the antibody — either through the Fc region, the Fab domain, or aggregated product clusters. Levy et al. (2014) showed that product-associated HCPs are a consistent subset across multiple mAbs, with specific interaction sites on the IgG molecule.

The key insight is that total HCP ELISA can report <10 ppm while a single high-risk HCP remains at a level sufficient to degrade polysorbate within the product shelf life. This is why regulators increasingly expect orthogonal characterization by LC-MS/MS alongside total HCP quantitation.

HCP Detection: ELISA, LC-MS/MS, and Orthogonal Methods

HCP measurement is only as good as the assay’s ability to detect the full population of host proteins present. No single method provides complete coverage, which is why orthogonal approaches combining ELISA and mass spectrometry are now expected for late-stage development and BLA filings.

USP ⟨1132.1⟩, which became official in May 2025, provides best practices for HCP measurement by LC-MS/MS. This chapter signals the regulatory expectation that mass spectrometry data will accompany ELISA results in marketing applications, particularly for identifying and monitoring high-risk HCPs that ELISA antibodies may not cover.

Frequently Asked Questions

Related Tools

• Chromatography Column Calculator — Size columns, calculate loading capacity, and plan buffer volumes for Protein A, IEX, HIC, and mixed-mode steps.
• Protein A Resin Lifetime Calculator — Track DBC decay over cycles to balance resin cost against HCP clearance capacity.
• Filtration & TFF Calculator — Size sterile filters and UF/DF systems for final concentration and polishing hold steps.

References

1. Shukla AA, Hinckley P. Host cell protein clearance during protein A chromatography: Development of an improved column wash step. Biotechnology Progress. 2008;24(5):1115–1121. doi:10.1002/btpr.50
2. Jones M, Palackal N, Wang F, et al. “High-risk” host cell proteins (HCPs): A multi-company collaborative view. Biotechnology and Bioengineering. 2021;118(8):2870–2885. doi:10.1002/bit.27808
3. Levy NE, Valente KN, Choe LH, Lee KH, Lenhoff AM. Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing. Biotechnology and Bioengineering. 2014;111(5):904–912. doi:10.1002/bit.25158
4. Ito T, Lutz H, Tan L, et al. Host cell proteins in monoclonal antibody processing: Control, detection, and removal. Biotechnology Progress. 2024;40(4):e3448. doi:10.1002/btpr.3448
5. Lakatos D, Idler M, Stibitzky S, et al. Buffer system improves the removal of host cell protein impurities in monoclonal antibody purification. Biotechnology and Bioengineering. 2024;121(12):3944–3956. doi:10.1002/bit.28844